Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

30 results about "Plasma kallikrein activity" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Benzylamine derivatives as inhibitors of plasma kallikrein

ActiveUS20140213611A1Easy to doUseful solubilityAntibacterial agentsBiocideDiseasePlasma kallikrein inhibitor

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.

Benzylamine derivatives as inhibitors of plasma kallikrein

Benzylamine derivatives as inhibitors of plasma kallikrein

Benzylamine derivatives as inhibitors of plasma kallikrein

Owner:KALVISTA PHARMA

Heterocyclic derivates

ActiveUS9533987B2Easy to doUseful solubilityAntibacterial agentsOrganic active ingredientsDiseaseMedicine

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Heterocyclic derivates

Heterocyclic derivates

Heterocyclic derivates

Owner:KALVISTA PHARMA

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

ActiveUS20170305863A1Useful solubilityImprove solubilityAntibacterial agentsOrganic active ingredientsDiseaseMedicine

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Owner:KALVISTA PHARMA

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

ActiveUS20180319782A1Useful solubilityImprove solubilityOrganic active ingredientsSenses disorderDiseaseMedicine

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((HET) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Owner:KALVISTA PHARMA

Benzylamine derivatives

ActiveUS20160039752A1Good choiceUseful in treatmentBiocideSenses disorderDiseaseAmine derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

Benzylamine derivatives

Benzylamine derivatives

Benzylamine derivatives

Owner:KALVISTA PHARMA

Inhibitors of plasma kallikrein

ActiveUS10221161B2Useful solubilityImprove solubilityOrganic active ingredientsSenses disorderDiseaseMedicine

The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein. ##STR00001##

Inhibitors of plasma kallikrein

Inhibitors of plasma kallikrein

Inhibitors of plasma kallikrein

Owner:KALVISTA PHARMA

Benzylamine derivatives

ActiveUS9670157B2Useful solubilityImprove solubilityOrganic active ingredientsSenses disorderDiseaseAmine derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

Benzylamine derivatives

Benzylamine derivatives

Benzylamine derivatives

Owner:KALVISTA PHARMA

Bicyclic inhibitors

ActiveUS9738641B2Useful solubilityImprove solubilityAntibacterial agentsBiocideDiseaseCancer research

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, B, W, X and Y are as defined herein.

Bicyclic inhibitors

Bicyclic inhibitors

Bicyclic inhibitors

Owner:KALVISTA PHARMA

Inhibitors of plasma kallikrein

ActiveUS20160168123A1Useful solubilityImprove solubilityBiocideSenses disorderDiseaseMedicine

The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.

Inhibitors of plasma kallikrein

Inhibitors of plasma kallikrein

Inhibitors of plasma kallikrein

Owner:KALVISTA PHARMA

Human plasma kallikrein inhibitors

ActiveUS20180354906A1Antibacterial agentsOrganic active ingredientsDiseaseKinin

Disclosed are compounds of formula Ias described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Owner:BIOCRYST PHARM INC

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

ActiveUS10364238B2Useful solubilityImprove solubilityOrganic active ingredientsSenses disorderDiseaseMedicine

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Owner:KALVISTA PHARMA

Human plasma kallikrein inhibitors

ActiveUS10633345B2Antibacterial agentsOrganic active ingredientsDiseaseKinin

Disclosed are compounds of formula Ias described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also disclosed are pharmaceutical compositions comprising at least one such compound, and methods involving use of the compounds and compositions in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Owner:BIOCRYST PHARM INC

Heterocyclic derivates

ActiveUS20160108036A1Good choiceUseful in treatmentAntibacterial agentsBiocideDiseaseMedicine

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Heterocyclic derivates

Heterocyclic derivates

Heterocyclic derivates

Owner:KALVISTA PHARMA

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

ActiveUS10781181B2Useful solubilityImprove solubilityAntibacterial agentsOrganic active ingredientsDiseaseKinin

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

Owner:KALVISTA PHARMA

Benzylamine derivatives

ActiveUS9834513B2Easy to doUseful solubilitySenses disorderNervous disorderDiseaseAmine derivatives

The present invention provides compounds of formula (I):compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R3, R5 to R9, A, P, V, W, X, Y and Z are as defined herein.

Benzylamine derivatives

Benzylamine derivatives

Benzylamine derivatives

Owner:KALVISTA PHARMA

Human plasma kallikrein inhibitors

ActiveUS20180362458A1Senses disorderNervous disorderDiseaseKinin

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Owner:BIOCRYST PHARM INC

Human plasma kallikrein inhibitors

ActiveUS10562850B2Senses disorderNervous disorderDiseaseKinin

Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Human plasma kallikrein inhibitors

Owner:BIOCRYST PHARM INC

Pyrazole derivatives as plasma kallikrein inhibitors

ActiveUS20190218205A1Reduce retinal vascular permeabilityBetter pharmacokinetic profileOrganic active ingredientsSenses disorderPlasma kallikrein inhibitorCancer research

The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Pyrazole derivatives as plasma kallikrein inhibitors

Pyrazole derivatives as plasma kallikrein inhibitors

Pyrazole derivatives as plasma kallikrein inhibitors

Owner:KALVISTA PHARMA

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

ActiveCN113004284ANovel structureHigh activityOrganic active ingredientsSenses disorderDiseaseKinin

The invention provides a tetracyclic plasma kallikrein inhibitor compound which is novel in structure, good in activity and high in selectivity, and can be widely applied to prevention or treatment of diseases related to plasma kallikrein activity.

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

Owner:CHENGDU KANGHONG PHARMA GRP

Plasma kallikrein inhibitor

PendingCN114206852AImprove efficiencyHigh selectivityOrganic chemistryAntipyreticDiseaseKinin

The present invention provides compounds of formula (I); compositions comprising such compounds; the use of such compounds in therapy (e.g., in the treatment or prevention of diseases or conditions involving plasma kallikins activity); and methods of treating patients using such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Plasma kallikrein inhibitor

Plasma kallikrein inhibitor

Plasma kallikrein inhibitor

Owner:KALVISTA PHARMA

Inhibitors of plasma kallikrein

ActiveUS11242333B2Useful solubilityImprove solubilityOrganic active ingredientsSenses disorderDiseaseKinin

The present invention provides compounds of formula (I),compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.

Inhibitors of plasma kallikrein

Inhibitors of plasma kallikrein

Inhibitors of plasma kallikrein

Owner:KALVISTA PHARMA

Substituted pyridine n-oxide derivatives useful as a factor xia inhibitors

PendingUS20220315561A1Organic chemistryThromboembolic disorderKinin

The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and / or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.

Substituted pyridine n-oxide derivatives useful as a factor xia inhibitors

Substituted pyridine n-oxide derivatives useful as a factor xia inhibitors

Substituted pyridine n-oxide derivatives useful as a factor xia inhibitors

Owner:JANSSEN PHARMA NV

Enzyme inhibitors

ActiveUS20220048894A1Improved profileImprove solubilityOrganic chemistryAntipyreticDiseaseKinin

The present invention provides compounds of formula (I):compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Enzyme inhibitors

Enzyme inhibitors

Enzyme inhibitors

Owner:KALVISTA PHARMA

Benzylamine derivatives as inhibitors of plasma kallikrein

ActiveUS9051249B2Easy to doUseful solubilityAntibacterial agentsSenses disorderDiseaseKallikrein

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.

Benzylamine derivatives as inhibitors of plasma kallikrein

Benzylamine derivatives as inhibitors of plasma kallikrein

Benzylamine derivatives as inhibitors of plasma kallikrein

Owner:KALVISTA PHARMA

A substituted oxopyridine derivative

PendingUS20210147414A1Avoid interferenceHigh selectivityOrganic active ingredientsOrganic chemistryPerylene derivativesPlasma kallikrein activity

The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide, to processes for its preparation, to its use for the treatment and / or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.

A substituted oxopyridine derivative

A substituted oxopyridine derivative

A substituted oxopyridine derivative

Owner:BAYER PHARMA AG

Pyrazole derivatives as plasma kallikrein inhibitors

ActiveUS11180484B2Easy to doImprove solubilityOrganic active ingredientsSenses disorderDiseaseKinin

The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.

Pyrazole derivatives as plasma kallikrein inhibitors

Pyrazole derivatives as plasma kallikrein inhibitors

Pyrazole derivatives as plasma kallikrein inhibitors

Owner:KALVISTA PHARMA

Bicyclic inhibitors

ActiveUS20160185773A1Useful solubilityImprove solubilityAntibacterial agentsBiocideDiseaseKinin

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, B, W, X and Y are as defined herein.

Bicyclic inhibitors

Bicyclic inhibitors

Bicyclic inhibitors

Owner:KALVISTA PHARMA

Tricyclic compound as plasma kallikrein inhibitor and application thereof

ActiveCN113004286ANovel structureHigh activityOrganic active ingredientsSenses disorderDiseaseKinin

The invention provides a tricyclic plasma kallikrein inhibitor compound which is novel in structure, good in activity and high in selectivity. The tricyclic plasma kallikrein inhibitor compound can be widely applied to prevention or treatment of diseases related to plasma kallikrein activity.

Tricyclic compound as plasma kallikrein inhibitor and application thereof

Tricyclic compound as plasma kallikrein inhibitor and application thereof

Tricyclic compound as plasma kallikrein inhibitor and application thereof

Owner:CHENGDU KANGHONG PHARMA GRP

Bicyclic pyridine n-oxide derivatives useful as a factor xia inhibitors

PendingUS20220306632A1Organic chemistryThromboembolic disorderKinin

The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and / or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.

Bicyclic pyridine n-oxide derivatives useful as a factor xia inhibitors

Bicyclic pyridine n-oxide derivatives useful as a factor xia inhibitors

Bicyclic pyridine n-oxide derivatives useful as a factor xia inhibitors

Owner:JANSSEN PHARMA NV

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

ActiveCN113004283ANovel structureHigh activityOrganic active ingredientsSenses disorderDiseaseKinin

The invention provides a tetracyclic plasma kallikrein inhibitor compound which is novel in structure, good in activity and high in selectivity, and can be widely applied to prevention or treatment of diseases related to plasma kallikrein activity.

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

Owner:CHENGDU KANGHONG PHARMA GRP

Popular searches

Enzyme Treated patient Heterocyclic derivatives Chemical compound Blood plasma Biology Medicinal chemistry Pharmacology Stereochemistry Disease injury

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com